KNKejing Niu

Kejing Niu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kejing Niu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Huijuan Yu

    State Key Laboratory of Chinese Medicine Modernization, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    2 shared publications
  • Fuxin Sun

    State Key Laboratory of Chinese Medicine Modernization, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Jianxiao Zheng

    State Key Laboratory of Chinese Medicine Modernization, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Jing Yang

    State Key Laboratory of Chinese Medicine Modernization, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China, tjutcm.edu.cn

    1 shared publication
  • Lixin Zhou

    State Key Laboratory of Chinese Medicine Modernization, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

    1 shared publication
  • Lulu Ma

    State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, No. 10 Poyanghu Road West Area Tuanbo New Town Jinghai District, Tianjin, 301617, China, tjutcm.edu.cn

    1 shared publication

Latest Publications

  • Open Access

    Integrated NMR, HPLC-Chemometrics, and Network Pharmacology Strategy for Quality Assessment and Mechanism Elucidation of Gelatinous Chinese Medicines

    by Lixin Zhou, Jianxiao Zheng, Ying Li, Kejing Niu, Fuxin Sun, Xin Chai, Yuefei Wang, Huijuan Yu

    Gelatinous Chinese medicines (GCMs), such as Ejiao, are animal-derived solid preparations traditionally used for blood and qi deficiency. With growing market demand, adulteration has become a critical quality concern. This study established a multimodal quality assessment system for GCMs. Using 1H NMR, we characterized the acid hydrolysates of GCMs and identified 17 components, including 16 total hydrolysable amino acids and taurine, revealing compositional similarity across seven GCMs. Stability studies under acid hydrolysis were conducted on 19 amino acids, all of which remained stable except methionin, cystine, and tryptophan, leading to the selection of the remaining 16 amino acids as target analytes. A pre-column derivatization–HPLC method was validated for the quantification of 16 total hydrolysable amino acids, showing excellent linearity (r2 > 0.999), high precision (RSD < 2.71%), and satisfactory recoveries (90.74–109.3%). Content determination of 65 batches revealed batch-to-batch variations in total hydrolysable amino acid profiles. Combined with chemometrics, the method successfully discriminated dermal, horn, bone, and shell glues, and further enabled subcategory differentiation. Network pharmacology analysis suggested that these amino acid components may interact with key targets (e.g., GRM5, GABRA1, GABBR2) and pathways, primarily neuroactive ligand–receptor interaction. Collectively, this integrated analytical and network-based strategy not only supports chemical authentication but also provides insights into the potential molecular basis of the traditionally described restorative effects of GCMs, offering a scientific foundation for their modernization and international recognition.

  • Open Access

    Quantitative Analysis of Flavonols and Their Glycosides and Gastrointestinal Transformation of Flavonol Glycosides in Yinxing Mihuan Oral Solution

    by Yun Lyu, Wenqian Cheng, Kejing Niu, Shaoqing He, Lulu Ma, Jing Yang, Huijuan Yu

    Yinxing Mihuan Oral Solution (YMOS) is extensively utilized in the clinical treatment of cardiovascular and cerebrovascular diseases (CCVDs), with flavonols and their glycosides identified as the primary active ingredients. Currently, there are relatively few established quantitative methods available for analyzing flavonols and their glycosides, and the research regarding their transformation patterns under simulated gastrointestinal conditions is still limited. In this study, network pharmacology was employed to predict the active compounds and targets of YMOS associated with cardiovascular and cerebrovascular protection. A comprehensive network integrating compounds, targets, bioactivities, and CCVDs was meticulously constructed for 10 flavonol glycosides and their aglycones. It revealed that these compounds exert their blood circulation–promoting and blood stasis–eliminating effects by modulating 20 key targets, highlighting their therapeutic potential in CCVDs treatment. Furthermore, we quantitatively analyzed the 10 targeted flavonols and their glycosides in YMOS using ultra‐performance liquid chromatography (UPLC), demonstrating consistent flavonoid levels across all tested samples. This method was also employed to investigate biotransformation rules between flavonol glycosides and their aglycones in vitro. Notably, it was observed that flavonol glycosides undergo a deglycosylation reaction in the rat’s intestinal microbial culture medium, which was witnessed in a relatively stable manner under the simulated artificial gastrointestinal fluid. These findings provide important scientific insights into the mechanism of action and the quality control of YMOS.